Ultragenyx PharmaceuticalRARE
Recorded

Ultragenyx Pharmaceutical 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration59 minParticipants21

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon and welcome to the Ultragenyx Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A portion of the call. It is now my pleasure to turn the call over to Joshua Higa, Chief of Staff and Vice President of Investor Relations.

Joshua HigaChief of Staff and VP of Investor Relations

Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President, Howard Horn, Chief Financial Officer, Erik Harris, Chief Commercial Officer, and Eric Crombez, Chief Medical Officer. I would like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I will now turn the call over to Emil.

Emil KakkisCEO and President

Thanks, Josh, and good afternoon, everyone. The third quarter was a significant one for Ultragenyx in many ways. In August and September, the FDA approved GENGLYCOS for glycogen storage disease type Ia and FAYUVI for Sanfilippo syndrome type A. These approvals are the result of years of work by our teams and the original scientists, as well as the families, patients, and investigators who took part in the studies. We also saw the disappointing data from the GTX-102 phase III that surprised us, despite compelling phase II data, which now has necessitated significant reductions across the company. These actions will bring our cost structure in line with our revenue. This enables us to be well-positioned to continue commercializing our six products for patients with rare diseases and thoughtfully invest in our development programs, all while becoming a profitable company next year.

Emil KakkisCEO and President

While the clinical study miss on an important program that could have created great value has challenged us, we should recognize all that the company has successfully accomplished in its 12 years as a public company. We now have six product approvals for the first-ever treatment indications across multiple treatment modalities and are driving revenue growth globally of about 20% per year for multiple years, heading to a billion-plus in revenue and profitability. While today we acknowledge a setback, when I started the company with $2 million and a secretary, I would have been surprised and inspired to know that we had become a highly respected and admired team of a thousand professionals treating thousands of patients with rare and ultra-rare diseases worldwide.

Emil KakkisCEO and President

There is more work to do, and we will today outline the steps we are taking to move the company to its next stage as a profitable company driving commercialization and development of first-ever treatments for rare diseases. To begin with, I'll focus on the launch of our two new gene therapy products. Both these products provide meaningful and transformative options for these rare disease patients and their families. For people living with glycogen storage disease type Ia, managing the disease means taking cornstarch every few hours, day and night, because a missed dose can lead to potentially life-threatening hypoglycemia. GENGLYCOS is the first FDA-approved treatment option for these patients and has the potential to reduce their dependence on cornstarch, easing the constant burden of care that defines their lives.

Emil KakkisCEO and President

The second approval we received in the quarter was for Sanfilippo syndrome type A, which is a fatal neurologic disease that begins in early childhood. At birth, these children appear normal, achieving development milestones just like their peers. This continues for the first months, but then stops, and over the next few years, as the children progressively lose cognition, language, and motor function until they become unresponsive and bedridden for years before death. Until now, families affected by Sanfilippo syndrome type A have had no approved therapy. FAYUVI is now available to these families as a single IV infusion done as an outpatient, giving them an option to meaningfully change their children's future. This is the hope that gene therapy was supposed to provide. These approvals come at a time that our clinical study failed to prove efficacy with GTX-102 for Angelman syndrome.

Emil KakkisCEO and President

Despite having some cases with transformative changes in phase II, which creates such a strong bond between us and the community, this result required us to discontinue the clinical program. It also necessitated a comprehensive review of all our expenses and priorities, with the goal of reducing our operating costs to be in line with our revenue to achieve meaningful profitability now and in the future, while still growing our business. Reduction expenses and ending a program necessarily includes actions to substantially reduce our workforce, and we are deeply grateful for the contribution of those who are impacted and are committed to providing support and resources to them during this transition. While this process was ongoing, we evaluated our UX701 gene therapy for Wilson disease and found it did not meet our criteria to advance to phase III.

Emil KakkisCEO and President

Given the need to further reduce expenses, we've also made the decision to terminate the UX701 program for Wilson disease rather than try to pursue improvements. The dose finding data, including data from cohort four, showed clinical activity in some patients, but we did not observe a majority of patients achieve a sufficient biochemical response and eliminate standard of care therapy. UX701 demonstrated a favorable safety profile across all cohorts dosed. I do believe there are patients who had meaningful benefits, including some coming off their chelators and zinc therapy after receiving UX701. I also believe that gene therapy is a rational approach to treating Wilson disease better than it is treated today. Unfortunately, we are not able to continue investing to optimize the product for Wilson disease.

Emil KakkisCEO and President

We are working with clinical sites and patient advocacy groups to support study participants and the broader Wilson community through this transition. We expect to present the data from the completed study at an upcoming medical or scientific congress to ensure our learnings are available to the broader community. We thank all the patients and investigators for their contributions to the program. These were not easy decisions, but they position us to focus on launching GENGLYCOS and FAYUVI well, continuing to grow our base of commercial products, and achieving profitability in 2027 and going forward. Becoming a self-sustaining company will support our ambition to lead the future of rare disease medicine. I will now turn the call over to Chief Financial Officer Howard Horn, who will provide the detail on our expense reductions and our profitability.

Howard HornCFO

Thank you, Emil, and good afternoon, everyone. The details of our third quarter financials are available in our press release, and I am happy to address any questions on them during Q&A. Today, my comments will focus on guidance for 2026 and 2027, including more details and rationale on the expense reductions Emil just mentioned and our expectations for profitability. Starting with 2026 guidance, we are reaffirming our 2026 revenue guidance, specifically that we expect total 2026 revenue of $730 million-$760 million, which, as a reminder, excludes revenue from the launches of FAYUVI and GENGLYCOS, CRYSVITA 2026 revenue of $500 million-$520 million, and DOJOLVI 2026 revenue of $100 million-$110 million. We are also reaffirming our expectation that 2026 combined R&D and SG&A expenses will be flat to down low single digits versus 2025.

Howard HornCFO

This includes the impact of all of our expense reductions, as well as $30 million in severance and other non-recurring restructuring charges from the first half of the year, and approximately $25 million in severance and other non-recurring restructuring charges expected to impact the fourth quarter of the year. Shifting now to 2027 guidance. Consistent with our prior practice, we expect to provide full-year 2027 revenue guidance early in the new year. For 2027 expenses, we expect R&D expenses will be less than $350 million, representing a reduction of more than 50% from 2025 levels, and we expect the majority of our 2027 R&D will be in support of our commercial products. We expect 2027 SG&A expenses will be less than $375 million, representing an increase of up to 7% from 2025 levels. These R&D and SG&A expense expectations reflect meaningful spend reductions from our previous guidance.

Howard HornCFO

To achieve these targets, we have initiated substantial headcount and expense reductions. Actions we are implementing include reducing our headcount by approximately 20%, resulting in a revised workforce of approximately 1,000 employees, promptly completing the wind-down of all ongoing studies and related spend for GTX-102 for Angelman syndrome, terminating UX701 for Wilson disease, and reducing expenses across the company, including reducing our real estate footprint and right-sizing G&A expenses to fit our new profile. Spending in 2027 will be focused on our commercial efforts and our smaller targeted R&D footprint, including completing the phase III study for DTX301 for OTC deficiency, determining the path forward for UX143 for osteogenesis imperfecta, and measured spending to progress early-stage programs for future INDs. Today, we are also reaffirming our expectation to achieve full-year GAAP net income profitability in 2027 and expect to generate positive cash flow from operating activities for the year.

Howard HornCFO

The factors underlying our ability to achieve 2027 profitability are the same as I outlined on our call in August: continued revenue growth from our four existing products, plus contributions from our new gene therapy launches, and disciplined expense management and capital allocation, as we just discussed. Additionally, in October, we strengthened our balance sheet with non-dilutive capital through the sale of our two PRVs. The first transaction closed last week, and we expect the second to close before the end of the month. Net proceeds total approximately $350 million after shared payments to licensors and fees, and will be reflected as other income in our 2026 financial statements. Our projected profitability in 2027 is driven by our underlying business and does not include income from PRVs. Importantly, we now have the cash needed to reach profitability without the need for additional fundraising.

Howard HornCFO

Achieving and sustaining profitability has been a central goal of the company, and we're grateful to be in a position to deliver it. Finally, in closing, reductions in force are one of the most challenging parts of operating a business, and I want to echo Emil's earlier comments of gratitude to our departing colleagues for their contributions to Ultragenyx. With that, I'll turn the call to our Chief Commercial Officer, Erik Harris, to provide more detail on the performance of our current products and our two launches.

Erik HarrisChief Commercial Officer

Thank you, and good afternoon, everyone. It has been an exciting few months for our commercial team, with the approvals of GENGLYCOS in August and FAYUVI in September, bringing our fifth and sixth approved medicines to patients and our first two gene therapies. Our teams have spent years preparing for this moment, and I'm pleased by how seamlessly they moved from approval to launch, initiating the process to reach the patients and families who have been waiting for these treatments. I'll begin with an update on the gene therapy launches and then turn to the performance of our established products. In the U.S., the field team leading the launch of GENGLYCOS and FAYUVI is the same team which has been in place for years supporting DOJOLVI and MEPSEVII. Their strong relationships and experience calling on medical geneticists at the centers is a significant advantage as these launches ramp up.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day